Objective-Although statins are efficacious for lowering low-density lipoprotein cholesterol, there is wide interindividual variation in response. We tested the extent to which combined effects of common alleles of LDLR and HMGCR can contribute to this variability. Methods and Results-Haplotypes in the LDLR 3Ј-untranslated region (3-UTR) were tested for association with lipid-lowering response to simvastatin treatment in the Cholesterol and Pharmacogenetics trial (335 blacks and 609 whites). LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (Pϭ0.0002 to 0.03) in blacks but not whites. The combined presence of LDLR L5 and previously described HMGCR haplotypes in blacks was associated with significantly attenuated apolipoprotein B reduction (Ϫ22.4Ϯ1.5%, Nϭ89) compared with both noncarriers (Ϫ30.6Ϯ1.5%, Nϭ78, Pϭ0.0001) and carriers of either individual haplotype (Ϫ28.2Ϯ1.1%, Nϭ158, Pϭ0.001). We observed similar differences when measuring simvastatin-mediated induction of low-density lipoprotein receptor surface expression using lymphoblast cell lines (Pϭ0.03). Conclusion-We have identified a common LDLR 3-UTR haplotype that is associated with attenuated lipid-lowering response to simvastatin treatment. Response was further reduced in individuals with both LDLR and previously described HMGCR haplotypes. Previously identified racial differences in statin efficacy were partially explained by the greater prevalence of these combined haplotypes in blacks. 
S
tatins are prescribed for the prevention and treatment of cardiovascular disease and work primarily to lower lowdensity lipoprotein cholesterol (LDLC). [1] [2] [3] [4] Despite widespread use of statins, lipid-lowering response is variable, and many patients fail to meet lipid-lowering goals. 5, 6 Variation in response is influenced by multiple factors, including age, sex, and racial ancestry. 7 For example, blacks have, on average, a lesser response to a given statin dose in comparison with whites. 7 Although common sequence variants in several candidate genes, including HMGCR and APOE, have been associated with alterations in lipid-lowering response to statin treatment, 8 -11 each of these associations accounts for a relatively small portion of the total variance in statin response. Hence, the genetic contribution to variability in statin-mediated lipid reductions likely results from multiple polymorphisms with small individual effects.
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, and genetic variation in HMGCR has been associated with attenuated lipid-lowering response to statin treatment. 8, 9, 12, 13 In the Cholesterol and Pharmacogenetics (CAP) study, we found that certain HMGCR haplotypes were associated with smaller simvastatin-mediated lipid reductions in blacks but not in whites 9 and that genetically influenced HMGCR alternative splicing contributed substantially to reduced statin response. 14 Although reduced cholesterol synthesis may contribute to statin-mediated reduction of LDLC, the primary mechanism for this effect is increased plasma low-density lipoprotein (LDL) clearance due to secondary upregulation of LDL receptor (LDLR) expression. 15 Variation at the LDLR locus is known to influence LDLC levels. 16, 17 Rare loss of function LDLR mutations are causative for familial hypercholesterolemia and the functional severity of these mutations has been associated with statin efficacy. 18 -20 Common LDLR DNA polymorphisms also have been associated with interindividual variation in LDLC, as well as other lipid and lipopro-tein traits, 16, [21] [22] [23] [24] and these variants are thought to mediate changes in LDLR protein expression or regulation. There is recent evidence that the 3Ј-untranslated region (3-UTR) of LDLR is required for berberine-mediated LDLC reduction through a mechanism that increases LDLR mRNA stability. 25 Single-nucleotide polymorphisms (SNPs) in the 3-UTR have been associated with in vivo LDLC levels, as well as in vitro LDLR mRNA stability, 26 and variation in this region may also influence statin-mediated lipid reduction. 27 To further explore this latter possibility, we assessed the contribution of common sequence variations in the LDLR 3-UTR to statininduced changes in lipids and lipoproteins in participants of the CAP trial. We also determined the combined influence of HMGCR and LDLR DNA variation on simvastatin-mediated lipid reductions.
Methods

Study Population
The CAP trial enrolled 944 participants in a 6-week simvastatin trial (40 mg/day) that was designed to examine genetic factors affecting simvastatin-mediated changes in lipids and lipoproteins. 7 This trial is registered at ClinicalTrials.gov (NCT00451828). Participants were healthy adult volunteers who self-reported either black (Nϭ335) or white (Nϭ609) ancestry. They were recruited at either the University of California, Los Angeles, School of Medicine (Los Angeles, Calif) or at San Francisco General Hospital (San Francisco, Calif). Informed consent was obtained and approved by the institutional review boards at those institutions and included approval for future genetic studies related to statin efficacy. Baseline health and demographic information were obtained at enrollment. Fasting plasma was collected at 2 pretreatment time points (screen visit and enrollment visit) and at 2 posttreatment time points (4 and 6 weeks of treatment). Lipids and lipoproteins were measured at all 4 time points. Total cholesterol (TC), triglyceride, apolipoprotein B (apoB), and highdensity lipoprotein cholesterol (HDLC) were measured using an Express 550 Plus analyzer (Ciba Corning, Oberlin, Ohio) in a laboratory that was monitored for consistency by the Centers for Disease Control-National Heart, Lung, and Blood Institute standardization program as described previously. 7 LDL cholesterol (LDLC) was calculated by the Friedewald equation. 28 Because TC, HDLC, and triglycerides were not significantly different between screen and enrollment, the average of these 2 measurements was used as the pretreatment value to minimize technical variation. For the same reason, the average of 4-and 6-week measurements was used as the posttreatment value. ApoB was measured only at enrollment and after 6 weeks.
Identification of tagSNPs and Haplotypes
DNA variants in the LDLR 3-UTR (2539 base pairs, chromosome 19:11,241,995 to 11,244,534 on the GRCh37 reference sequence) were identified by Sanger resequencing of genomic DNA samples derived from 24 blacks and 23 whites from the Coriell repository. Overlapping segments were polymerase chain reaction amplified and sequenced using 5% BigDye Terminatory (BDT) version 3.1 sequencing chemistry (Applied Biosystems) in MJ Tetrad PTC-225 thermocyclers, and chromatograms were generated from these reaction products on ABI3730 capillary sequencers. Sequences were base-called using Phred and assembled into contigs using Phrap. All sequence contigs were assembled and screened using Polyphred, and for confirmation, all variant sites were visually inspected using Consed. We identified 23 variable sites (15 with minor allele frequency greater than 5%), and these were mapped using the University of California, Santa Cruz, Golden Path human genome assembly as the reference sequence. Six tagSNPs were identified using LD select (r 2 Ͼ0.80 and minor allele frequency [MAF]Ͼ0.05), 29, 30 and these were genotyped in all CAP participants using a combination of MassArray technology (rs1433099, rs7254521, rs2738467, rs17249057; Sequenom, San Diego, Calif) and Haplotypes were inferred separately in black and white participants of the CAP trial using PHASE2.0. 31 Six common haplotypes (Table 1, MAFϾ0.05) were inferred, and these were tested for associations with statin-mediated lipid reduction. Cladogram analysis was performed using TCS, version 1.21. 32 Global association of LDLR 3-UTR haplotypes was assessed by analysis of covariance both within the entire CAP population and separately in blacks and in whites.
Quantification of LDLR Surface Protein Expression in Lymphoblast Cell Lines
Lymphoblast cell lines (LCLs) were derived from all CAP participants by Epstein-Barr virus transformation of lymphocytes isolated from blood samples collected at enrollment visit. [33] [34] [35] LCLs were grown at 37°C (95% O 2 , 5% CO 2 ) in RPMI 1640 medium (Invitrogen, Carlsbad, Calif) supplemented with 10% fetal bovine serum (HyClone, Logan, Utah), 500 U/mL penicillin/streptomycin, and 2 nmol/L GlutaMAX (Invitrogen). Simvastatin was provided by Merck Inc. (Whitehouse Station, NJ) and was 98% converted to the active form (␤-hydroxy simvastatin acid) by heating to 50°C for 1 hour in 0.1N NaOH before use. 36 ␤-Hydroxy simvastatin acid concentrations were quantified by liquid chromatography-tandem mass spectrometry using a Kromasil C18 column (Keystone Scientific, Bellfonte, Penn) on a Shimadzu LC-10AD HPLC system (Shimadzu, Columbia, Md) connected to a Waters Micromass Quattro LC triple quadrupole mass spectrometer (Waters, Milford, Mass). 37 LCLs (Nϭ193) derived from blacks were normalized to a uniform cell density and exposed to 2 mol/L simvastatin or sham buffer for 24 hours. 14 LDLR protein was quantified in arbitrary units (A.U.) following exposures as previously described. 25 Briefly, 4ϫ10 6 cells were incubated with a monoclonal LDLR antibody diluted 1:50, washed, and subsequently incubated with anti-IgGfluorescein isothiocyanate labeled antibody diluted 1:400. An isotype-matched normal mouse IgG diluted 1:50 was used to quantify background fluorescence. All antibodies were purchased from Santa Cruz Biosciences (Santa Cruz, Calif). Fluorescent intensity in 10,000 gated events was measured on a BD FACSCalibur.
Statistical Analysis
Associations of haplotypes with lipids, lipoproteins, and LDLR expression were analyzed by analysis of covariance using the dominant model and including age, sex, body mass index (BMI), and smoking status as covariates. Associations were repeated after additional adjustment for HMGCR haplotypes H2 and H7, which have previously been associated with attenuated simvastatin response in this population. 9 To ensure that analyses were not influenced by nonnormal trait distributions, we also tested for associations using nonparametric analyses. Because these did not change any of the statistical findings, the results are reported using parametric analysis. For SNP analyses and haplotype analyses described in Table 2 , correction for multiple testing was performed using QVALUE. 38 All statistical analyses were performed using JMP version 7.0 software (SAS, Cary, NC).
Results
Association of LDLR 3-UTR L5 Haplotype With In Vivo Simvastatin-Mediated Lipid Reductions and In Vitro LDLR Expression
LDLR 3-UTR haplotypes were inferred based on tagSNPs selected to cover DNA variation across the entire 3-UTR, including the AU-rich elements (AREs) and alu-rich regions ( Figure 1A ). For all 6 haplotypes, allelic prevalence was significantly different between blacks and whites ( Figure  1A) . LDLR 3-UTR haplotype 5 (LDLR L5) was inferred to contain the major allele at all tagSNPs and was more prevalent in blacks ( Figures 1A and 1B) . The alleles represented by this haplotype were also observed in the chimpanzee genome, indicating that they represent the ancestral alleles. Although individual SNPs were not associated with statin-mediated lipid changes in either the CAP population as a whole or within blacks or whites separately, haplotypes within this region were associated with statin-mediated changes in lipids and lipoproteins using an omnibus haplotype test. We next assessed the associations of individual LDLR 3-UTR haplotypes with statin-mediated lipid changes. There was no evidence for an association of the LDLR 3-UTR haplotypes with statin response among whites. Among blacks, we observed a significant association of LDLR L5 with attenuated statin-mediated percentage changes in TC, apoB, and non-HDLC (Table 1) . ApoB reductions were lower in both homozygous LDLR L5 carriers (Ϫ19.2Ϯ3.8 mg/dL apoB, Nϭ14, Pϭ0.02) and in heterozygous LDLR L5 carriers (Ϫ21.4Ϯ1.4 mg/dL apoB, Nϭ114, PϽ0.0001) in comparison with noncarriers (Ϫ29.2Ϯ1.1 mg/dL apoB, Nϭ207, probability value for trend: 0.0004). Similar associations were observed for TC, LDLC, and non-HDLC (data not shown). Associations of LDLR L5 with attenuated statin-mediated changes in all 4 traits remained significant after adjusting for the previously identified HMGCR haplotypes (H2 and H7) ( Table 1) . 9 LDLR L5 carriers demonstrated a nonsignificant trend toward reduced pretreatment and elevated posttreatment concentrations for all 4 traits ( Table 2 ). In whites, no association of LDLR L5 was observed with either pretreatment lipids or statin-mediated changes in these traits (Table 2) .
To identify the basis for these findings, we tested for an association of LDLR L5 with change in expression of LDLR surface protein in response to in vitro simvastatin exposure in LCLs derived from black CAP participants. LDLR surface protein expression was significantly induced in response to simvastatin exposure (1.45Ϯ0.06 fold change, Nϭ193, Pϭ0.002) in a manner that was correlated with in vivo statin-mediated decrease in apoB in the individuals from whom these cell lines were derived (Figure 2A) . LDLR surface protein expression was not associated with LDLR L5 following exposure to either sham buffer or simvastatin ( Figure 2B and 2C) . However, LDLR induction was significantly reduced in cell lines derived from LDLR L5 carriers in comparison with noncarriers ( Figure 2D ).
Combined Influence of LDLR L5 and HMGCR H2/H7 Haplotypes on In Vivo and In Vitro Simvastatin Response
We have previously observed that, similar to the findings for the LDLR L5 haplotype reported here, HMGCR H2 and H7 haplotypes were also associated with reduced LDL response to simvastatin in blacks. This raises the possibility of additive effects of LDLR L5 and HMGCR H2 or H7 (H2/H7) on simvastatin response. Indeed, we observed that carriers of both haplotypes (L5ϩH2/H7) had significantly attenuated LDLC reductions in comparison with carriers of the LDLR L5 haplotype alone (Pϭ0.05) and in comparison with carriers of neither haplotype (Pϭ0.0002, Figure 3A) , with a similar trend observed in comparison with HMGCR H2/H7-only carriers (Pϭ0.06). Carriers of both alleles also demonstrated significantly lower simvastatin-mediated apoB reductions in comparison with HMGCR H2/H7-only carriers (Pϭ0.03) and in comparison with carriers of neither haplotype (PϽ0.0001, Figure 3B ), with a nonsignificant trend in comparison with LDLR L5 carriers (Pϭ0.09). We tested for association of the combined L5ϩH2/H7 haplotype with in vitro LDLR induction following simvastatin exposure ( Figure 3C ) and found that response was significantly reduced in L5ϩH2/H7 carriers compared with HMGCR H2/H7-only carriers and noncar- Figure 2 ) is due predominantly to the combined L5ϩH2/H7 carriers.
riers. No difference in LDLR induction was detected between noncarriers and carriers of either individual haplotype. This indicates that the association of LDLR L5 with attenuated LDLR induction (
We next assessed whether inclusion of both haplotypes into a combined model would be predictive of statin response in blacks. We categorized individuals by lipid-lowering response as carriers of 2 haplotypes (both LDLR L5 and HMGCR H2/H7), 1 haplotype (either the LDLR L5 or HMGCR H2/H7 haplotypes), or 0 haplotypes (neither haplotype). We observed a significant additive association of LDLR/HMGCR haplotypes with statin-induced reduction of LDLC and apoB (Figure 4) , as well as TC and non-HDLC (data not shown). In support of these observations, in vitro LDLR protein induction in response to simvastatin was reduced in combined L5ϩH2/H7 carriers (0.74Ϯ0.09 A.U., Nϭ57 2-haplotype carriers, versus 1.02Ϯ0.06 A.U., Nϭ97 1-haplotype carriers, versus 0.97Ϯ0.10 A.U., Nϭ39 noncarriers, Pϭ0.03). These associations were not observed in white CAP participants (data not shown), in whom the prevalence of the combined haplotypes was significantly lower (Nϭ89 blacks [14 
Discussion
In this study, we have found that DNA variation in the 3-UTR of LDLR is associated with diminished effects of statin on in vivo lipid reductions and on in vitro LDLR induction. We further demonstrated that there is a combined influence on statin response of the L5 LDLR 3-UTR haplotype and the HMGCR haplotypes that we have previously shown to be associated with statin efficacy, such that carriers of both haplotypes had significantly attenuated statin-mediated changes in LDLC and LDLR in comparison with either noncarriers or carriers of individual haplotypes. Furthermore, these effects were more evident in blacks than in whites. Although this may be the result of differences between blacks and whites in the underlying sequence variation that is tagged by these haplotypes, it is more likely the result of differences in haplotype prevalence. Indeed, these haplotypes were significantly more prevalent in blacks than in whites for both HMGCR (32% blacks versus 2% whites, PϽ0.0001) 9 and LDLR (21% blacks versus 3% whites, PϽ0.0001). Interestingly, both the LDLR and the HMGCR haplotypes were specifically represented by the ancestral alleles at all tagSNPs, suggesting that they represent the ancestral haplotypes. 9 Furthermore, the combination of both LDLR and HMGCR haplotypes was most strongly associated with attenuated response, and this combined genotype was practically absent in the whites within this study population (prevalence, Ͻ1%).
The LDLR 3-UTR haplotypes describe common variation that spans the entire LDLR 3-UTR, including the proximal AREs and the distal Alu-rich region. The AREs have been shown to be involved in mediating the LDLC reduction induced by the herbal product berberine. 25 This region promotes mRNA decay and binds to multiple proteins, including several involved in mRNA processing and splicing. 39, 40 In addition to the ARE region, LDLR L5 is also represented by the ancestral alleles of SNPs located within the Alu-rich region. This region is responsible for transcriptional stability in response to protein kinase C activation. 39 The Alu-rich region is a rapidly mutagenized genomic region, but the influence on LDLR function of SNPs within this region has not previously been studied. 41, 42 The present study has demonstrated that the LDLR 3-UTR ancestral haplotype, which is most prevalent in blacks, is associated with attenuated statin response. Because LDLR L5 was represented by ancestral alleles at all tagSNPs, these data suggest that multiple SNPs within the region may modify functionality of this region. Additional studies are necessary to determine the functional influence of individual SNPs within the haplotype on statin response.
Previous LDLR 3-UTR association analyses focusing on the ARE region have demonstrated that the ancestral haplotype within this region was associated with increased mRNA stability but, contrary to expectation, with increased LDLC in white populations. 26, 27 Association with increased LDLC may reflect linkage disequilibrium between this region and other functional regions of the LDLR gene. Within our extended LDLR 3-UTR haplotype analysis, the ancestral tagSNPs within the ARE region are represented by 3 haplotypes: LDLR L5, for which prevalence is low in whites (MAFϭ0.03), and LDLR L1 and L6, which are more common in whites (MAFϭ0.22 for each). Both LDLR L1 and L6 are in linkage disequilibrium with an exonic SNP (rs688) that induces LDLR alternate splicing and is associated with increased LDLC. 43 This suggests that although the ARE region may influence LDLR mRNA stability, the previously described association of this region with increased LDLC in whites may reflect the functional consequences of variation outside of the 3-UTR. In contrast, LDLR L5 was not in linkage disequilibrium with rs688 or any other LDLR SNPs identified by genome-wide association study to be associated with LDLC (Supplemental Table II ). 16, [21] [22] [23] [24] 29, 31, [43] [44] [45] Furthermore, we saw no indication that any of these genome-wide association study-identified SNPs were associated with statin-medicated LDLC reduction within our own genomewide association analysis, although they were all associated with untreated LDLC. 46 Studies to assess the influence of LDLR L5 on mRNA stability and processing are ongoing.
Both LDLR L5 and the HMGCR H2/H7 haplotypes were independently associated with reduced simvastatin response, specifically in black but not white CAP participants. The combination of these haplotypes was strongly associated with diminished statin response such that LDLR L5ϩHMGCR H2/H7 carriers exhibited significantly attenuated lipid reductions in comparison with carriers of either individual haplotype. Reduced induction of the LDLR surface protein was also observed in simvastatin-exposed LCLs derived from carriers of both haplotypes in comparison with cell lines derived from carriers of individual haplotypes. The contribution of these individual haplotypes to the magnitude of variation in statin response was small, with either haplotype explaining 1% to 4% of the variance in lipid response traits in blacks. However, these contributions are additive, with the combined haplotype state accounting for 3% to 6% of the variation in lipid-lowering simvastatin response in blacks. Indeed, the presence of both haplotypes diminished LDLC reduction by 17.0% and apoB reduction by 27.4% in blacks, suggesting the need for a greater statin dosage requirement in black carriers, because a doubling of dose yields a Ϸ6% further reduction in LDLC. 47, 48 In contrast, the combined haplotypes described less than 1% of the variance in statin response in whites, for whom the prevalence of the combined haplotype was much smaller (Ͻ1.0%). These data suggest that the effect of racial ancestry on lipid-lowering statin response is caused in part by differential prevalence of these LDLR and HMGCR haplotypes. Indeed, the effect of racial ancestry on lipid-lowering response to simvastatin was reduced to nonsignificance following adjustment for these haplotypes. In conclusion, these data suggest that the dissimilar simvastatin response observed between blacks and whites is due in part to the differential prevalence of multiple sites of genetic variation that have independent but compounded effects on statin efficacy. 
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